In patients with type 2 diabetes who are receiving antidiabetic treatment, circulating nesfatin-1 levels are decreased, as antidiabetic treatments target the reduction of blood glucose, increased insulin sensitivity, and controlled food intake. The gene discussed is NUCB2; the disease is type 2 diabetes mellitus.